Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice

Pemafibrate for primary biliary cholangitis with dyslipidemia: A proposal of a new treatment from Japan

(2022) Naoki Tanaka et al.   HEPATOLOGY RESEARCH

Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?

(2021) Jean-Charles Fruchart et al.   Current Atherosclerosis Reports

FGF21 Normalizes Plasma Glucose in Mouse Models of Type 1 Diabetes and Insulin Receptor Dysfunction

(2021) John L Diener et al.   ENDOCRINOLOGY

Pemafibrate Prevents Retinal Dysfunction in a Mouse Model of Unilateral Common Carotid Artery Occlusion

(2021) Deokho Lee et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Species Differences between Mouse and Human PPARα in Modulating the Hepatocarcinogenic Effects of Perinatal Exposure to a High-Affinity Human PPARα Agonist in Mice

(2021) Jennifer E Foreman et al.   TOXICOLOGICAL SCIENCES

The role of FGF21 in the pathogenesis of cardiovascular disease

(2021) Ying Zhang et al.   CHINESE MEDICAL JOURNAL

Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice

(2021) Kumiko Suto et al.   Journal of Atherosclerosis and Thrombosis

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases

(2020) Shizuya Yamashita et al.   Current Atherosclerosis Reports

Increased plasma concentrations of an antidyslipidemic drug pemafibrate co-administered with rifampicin or cyclosporine A in cynomolgus monkeys genotyped for the organic anion transporting polypeptide 1B1

(2020) Shin-ichiro Ogawa et al.   Drug Metabolism and Pharmacokinetics

PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice

(2020) Yaping Wang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content

(2020) Yusuke Sasaki et al.   Scientific Reports

Hyperlipidemia

(2020) Jeremy Stewart et al.   PEDIATRICS IN REVIEW

A novel selective PPARα modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms

(2020) Hiroshi Kawanishi et al.   PLoS One

Dietary Restriction Suppresses Steatosis-Associated Hepatic Tumorigenesis in Hepatitis C Virus Core Gene Transgenic Mice

(2020) Fangping Jia et al.   Liver Cancer

FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation

(2020) Helle Keinicke et al.   Endocrine Connections

Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet

(2020) Masatoki Yoshida et al.   Cardiovascular Diabetology

Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy

(2020) Yohei Tomita et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment

(2019) Koutaro Yokote et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases

(2019) Shizuya Yamashita et al.   Journal of Atherosclerosis and Thrombosis

Going Back to the Biology of FGF21: New Insights

(2019) Jo E. Lewis et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Gene Expression Profiles Induced by a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα) Pemafibrate

(2019) Yusuke Sasaki et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Pemafibrate Has High Bioavailability and is Principally Excreted via the Liver

(2018) Neil Hounslow et al.   ATHEROSCLEROSIS SUPPLEMENTS

FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1–7) Axis in Mice

(2018) Xuebo Pan et al.   Cell Metabolism

PPAR Agonists and Metabolic Syndrome: An Established Role?

(2018) Margherita Botta et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice

(2018) Masami Sairyo et al.   Journal of Atherosclerosis and Thrombosis

The Peroxisome Proliferator-Activated Receptor α (PPARα) Agonist Pemafibrate Protects against Diet-Induced Obesity in Mice

(2018) Masaya Araki et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Distinct but complementary contributions of PPAR isotypes to energy homeostasis

(2017) Vanessa Dubois et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting nuclear receptors for the treatment of fatty liver disease

(2017) Naoki Tanaka et al.   PHARMACOLOGY & THERAPEUTICS

Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis

(2017) Yasushi Honda et al.   Scientific Reports

The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis

(2016) Nathalie Hennuyer et al.   ATHEROSCLEROSIS

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD

(2016) Alexandra Montagner et al.   GUT

Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet

(2015) Naoki Tanaka et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Transcriptome Analysis of K-877 (a Novel Selective PPARα Modulator (SPPARMα))-Regulated Genes in Primary Human Hepatocytes and the Mouse Liver

(2015) Sana Raza-Iqbal et al.   Journal of Atherosclerosis and Thrombosis

Effects of fibroblast growth factor 21 on the heart

(2015) Pongpan Tanajak et al.   JOURNAL OF ENDOCRINOLOGY

Patchy progress on obesity prevention: emerging examples, entrenched barriers, and new thinking

(2015) Christina A Roberto et al.   LANCET

Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet

(2014) Naoki Tanaka et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Triglyceride-lowering agents

(2014) Nariman F. Salakhutdinov et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Fibroblast growth factor 21 protects the heart from oxidative stress

(2014) Anna Planavila et al.   CARDIOVASCULAR RESEARCH

Adipocyte-specific Disruption of Fat-specific Protein 27 Causes Hepatosteatosis and Insulin Resistance in High-fat Diet-fed Mice

(2014) Naoki Tanaka et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Triglyceride: One molecule at the center of health and disease

(2012) Ira J. Goldberg   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

(2012) Akira Honda et al.   HEPATOLOGY

Fibroblast Growth Factor-21 (FGF21) Regulates Low-density Lipoprotein Receptor (LDLR) Levels in Cells via the E3-ubiquitin Ligase Mylip/Idol and the Canopy2 (Cnpy2)/Mylip-interacting Saposin-like Protein (Msap)

(2012) Hai Thi Do et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Fibrates and estimated glomerular filtration rate: observations from an outpatient clinic setting and clinical implications: Figure 1

(2012) Ahmed Abbas et al.   POSTGRADUATE MEDICAL JOURNAL

Effects of insulin resistance and hepatic lipid accumulation on hepatic mRNA expression levels of apoB, MTP and L-FABP in non-alcoholic fatty liver disease

(2011) NOBITO HIGUCHI et al.   Experimental and Therapeutic Medicine

Microsomal triglyceride transfer protein and nonalcoholic fatty liver disease

(2011) Isabel VA Pereira et al.   Expert Review of Gastroenterology & Hepatology

Bezafibrate at Clinically Relevant Doses Decreases Serum/Liver Triglycerides via Down-Regulation of Sterol Regulatory Element-Binding Protein-1c in Mice: A Novel Peroxisome Proliferator-Activated Receptor  -Independent Mechanism

(2009) T. Nakajima et al.   MOLECULAR PHARMACOLOGY

Myopathy with statin–fibrate combination therapy: clinical considerations

(2009) Terry A. Jacobson   Nature Reviews Endocrinology

Dose translation from animal to human studies revisited

(2007) Shannon Reagan-Shaw et al.   FASEB JOURNAL